tbuckley/cabot-search huggingface dataset:
Chromosome 14q imbalances and pathways associated with resistance to antiangiogenic therapy in clear cell renal cell carcinoma.
Authors: E. Jonasch, K. Alvarez, L. Peterson, N. M. Tannir, K. Sircar, P. Tamboli, F. A. Monzon
Journal: Journal of Clinical Oncology (2011)

339 Background: Antiangiogenic agents are used to treat metastatic clear cell renal cell carcinoma (ccRCC). Currently there are no biomarkers of therapeutic efficacy for these agents. Hypoxia inducible factor (HIF) alpha ratios have been linked to phenotypically distinct ccRCC subpopulations. The HIF1 alpha gene is located on chromosome 14q. In this study, the goal was to determine whether chromosomal imbalances identified with SNP arrays are linked to HIF ratios, and to clinical outcome. Methods: We obtained archival FFPE tumor specimens from 56 patients with mRCC treated with sorafenib or bevacizumab. DNA from the FFPE blocks was analyzed with Affymetrix 250K Nsp SNP microarrays. We identified the presence of genomic imbalances and loss of heterozygosity (LOH) to obtain virtual karyotypes. We then evaluated candidate genes in gain/lost chromosomal regions by qPCR and immunohistochemistry (IHC) in the bevacizumab treated specimens. Results: In the bevacizumab cohort, HIF1-alpha containing14q loss showed a significant association with worse response to treatment (CR/ PR vs. SD/PD, Fisher exact test, p = 0.0473). In addition, HIF1A mRNA expression was significantly reduced in all samples with 14q loss and was associated with PFS (HR = 2.29, 95% CI = 1.01-5.16, p = 0.045). HIF-1alpha protein expression was also reduced in samples with 14q loss. Conclusions: Chromosomal imbalances are associated with outcomes in ccRCC patients treated with antiangiogenic agents, and can lead to changes in gene expression. Low HIF1A expression was strongly correlated with shorter PFS. We hypothesize that loss of 14q could lead to an imbalance in HIF-1alpha/HIF-2alpha activity, leading to increased HIF-2alpha and enhanced c-Myc expression, which improves tumor cell viability and engenders resistance to cellular stress induced by antiangiogenic therapy. No significant financial relationships to disclose.
Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas
Authors: Stephen J. Schuster, Jakub Svoboda, Sunita Dwivedy Nasta, David L. Porter, Elise A. Chong, Yolanda Mahnke, Simon F. Lacey, J. Joseph Melenhorst, Anne Chew, Gaurav Shah, Jens Hasskarl, Manuel Litchman, Mariusz A. Wasik, Daniel J. Landsburg, Anthony R. Mato, Alfred L. Garfall, Noelle V. Frey, Katherine T. Marcucci, Joanne Shea, Holly McConville, Zhaohui Zheng, Bruce L. Levine, Carl H. June
Journal: Blood (2014)
European Chromosome 6 Haplotypes Significantly Augment Fetal Hemoglobin Levels in Brazilian Sickle Cell Anemia Patients: Influence of Four HBS1L-MYB Intergenic Region SNPs
Authors: Flávia Costa Leonardo, Stephan Menzel, Ana Flavia Brugnerotto, Kleber Yotsumoto Fertrin, Marcos André Cavalcanti Bezerra, Aderson S Araujo, Fernando Ferreira Costa, Swee Lay Thein, Nicola Conran
Journal: Blood (2012)
Comparison of lesion size between preoperative imaging and postoperative histopathology in unifocal breast cancer.
Authors: C. R. Abraham, B. Whiteside, M. Schuster, D. Jones, J. Pollard, L. MacFarlan, K. Hena, M. A. Hena
Journal: Journal of Clinical Oncology (2011)

1087 Background: Patients with biopsy-proven Stage I and Stage II breast cancer usually undergo pre-operative magnetic resonance imaging (MRI) and/or ultrasound to delineate the margins of the lesion to be removed, to determine multicentric disease as well as evaluate the contralateral breast. The purpose of this study was to compare the findings of the two imaging modalities with the post-operative histopathology. Methods: The charts, images and pathology specimens of breast cancer patients treated in our surgical oncology clinic between 2007-2010 were retrospectively reviewed. The Stage I and II patients with unifocal disease had both an ultrasound and MRI examination of the breast as part of their pre-operative assessment. The estimated size of the lesion from pre-operative imaging was compared to the actual size measured microscopically in the pathology specimens. Results: Of 171 women with breast cancer treated during the study period, 27 consecutive patients had biopsy-proven Stage I or II unifocal disease. Compared to the sizes of the lesions on histopathology, there was better correlation with ultrasound than MRI. For lesions < 2 cm, both modalities overestimated the size of the lesion; for lesions > 2 cm both MRI and ultrasound underestimated the size of the lesion. A regression analysis was done. The regression equation is: US size(cm)= 0.339 + 0.710 T path size, and (R2= 68%) for ultrasound. For MRI, the regression equation is MRI size(cm)= 0.641 + 0.636 T path size, and (R2= 43%) for MRI. Conclusions: From these data we conclude that 1) ultrasound is the single most useful examination for pre-operative estimation of lesion size in Stage I and II unifocal breast cancer, and 2) surgeons performing breast conservation techniques for such patients should expect to remove a larger amount of tissue than suggested by pre-operative images for lesions over 2cm.
Advances in the Decision to Image or Not to Image—Reply
Authors: Jun Deng, John J. Kim
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Age over 55 Years at Diagnosis Increases Risk of Second Malignancies after Auto-Transplantation for Hodgkin's Lymphoma Patients
Authors: Sai Ravi Pingali, Rima Saliba, Paolo Anderlini, Chitra M. Hosing, Issa F. Khouri, Amin M. Alousi, Partow Kebriaei, Yago Nieto, Muzaffar H. Qazilbash, Michelle A. Fanale, Elizabeth J. Shpall, Richard E. Champlin, Uday R. Popat
Journal: Blood (2015)
Use of an Operating Room Scorecard—Keeping Score and Cutting Costs
Authors: Andrew M. Ibrahim, Justin B. Dimick
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Telomerase Inhibition with a Novel G-Quadruplex-Interactive Agent, Telomestatin: In Vitro and In Vivo Studies in Acute Leukemia.
Authors: Tetsuzo Tauchi, Kazuo Shin-ya, Goro Sashida, Masahiko Sumi, Akihiro Nakajima, Junko H. Ohyashiki, Kazuma Ohyashiki
Journal: Blood (2004)
Journal of Physiology, London
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Factors affecting lymphovascular invasion in node-positive breast cancer patients.
Authors: L. B. Cornwell, K. McMasters, A. B. Chagpar
Journal: Journal of Clinical Oncology (2011)

24 Background: Lymphatic and/or vascular invasion (LVI) is not uniformly reported in breast cancer tumors, and may be absent even in LN+ patients. The purpose of this study was to define factors associated with (a) the non-reporting of LVI, and (b) the finding of no LVI in LN+ patients. Methods: Data from 400 LN+ patients from a cohort of patients in a prospective multicenter study were reviewed. Institutional and clinicopathologic factors correlating with the reporting and finding of LVI were assessed using non-parametric statistical analysis. Results: Of the 400 LN+ patients in this cohort, LVI was not reported in 98 (24.5%) patients. Of the remaining 302 patients, LVI was reported as negative in 147 (48.7%). LVI was more often reported in later years (84.9% in 2001-2004 vs. 67.9% in 1997-2000, p&lt;0.001). The reporting of LVI did not vary significantly by region, teaching affiliation, community size, or the surgeon’s proportion of breast practice or number of cases. Further, reporting of LVI was not associated with surgery type, patient age, number of positive nodes, size of largest metastasis, nor extracapsular extension. LVI was, however, more frequently reported in larger tumors (median tumor size 2.0 cm vs. 1.8 cm, p=0.030). Despite the finding that LVI was more frequently reported in later years, the proportion of patients found to have LVI did not vary by year (53.3% in 2001-2004 vs. 49.3% in 1997-2000, p=0.565), region, teaching affiliation, community size, or surgeon practice. LVI positivity was associated with younger age (median age 53 vs. 60, p=0.001), larger tumors (median size 2.5 vs. 1.8 cm, p&lt;0.001), more positive lymph nodes (median 2.5 vs. 1, p&lt;0.001), more macrometastases (58.7% vs. 36.5%, p=0.002), and more extracapsular extension (70.3% vs. 46.0%, p=0.001). Conclusions: Reporting of LVI has improved in recent years, and while the rate of LVI positivity has not changed in LN+ patients, it remains associated with poor prognostic factors in this cohort. Therefore, reporting of LVI should be encouraged as a standard part of synoptic pathology reports for breast cancer patients, regardless of lymph node status.
Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS): Follow-up AML and Survival Results of a Randomized, Double-Blind, Placebo (PBO)-Controlled Study
Authors: Hagop M. Kantarjian, Ghulam J. Mufti, Pierre Fenaux, Mikkael A. Sekeres, Jeffrey Szer, Uwe Platzbecker, Andrea Kuendgen, Gianluca Gaidano, Wieslaw Wiktor-Jedrzejczak, John M. Bennett, Anne Meibohm, Allen S. Yang, Aristoteles Giagounidis
Journal: Blood (2012)
Abstract P076: Increased Incidence of Cardiovascular Disease Events Among Diabetes Patients with Complications
Authors: Ruben G Quek, Kathleen M Fox, Li Wang, Lu Li, Shravanthi R Gandra, Nathan D Wong
Journal: Circulation (2016)

Objective: To estimate the incidence of cardiovascular disease (CVD) events among T2DM patients across the number of diabetic or CHD RE complications. Research Design and Methods: Adult (aged ≥18 years) hyperlipidemic patients diagnosed with T2DM who initiated statins and/or ezetimibe from January 2007 to June 2011 were identified retrospectively from the IMS LifeLink Pharmetrics Plus™ commercial claims database. The index date was the initiation date of the statin and/or ezetimibe after ≥ 12 months of continuous health plan eligibility. Incident CVD events among those with a history of multiple (if any) diabetic and CHD RE complications were assessed for ≥ 12 months post-index date. A subset analysis was performed among patients aged ≥ 40 years. A Cox proportional hazard model was performed to assess the relationship between number of complications and incident CVD events. Results: A total of 136,854 hyperlipidemic patients had T2DM during the 12 months pre-index (baseline) period. The mean age was 56 years old (±10.5) and 55.8% of the population were male. Those with ≥ 1 complication(s) represented ~18% of the patients (17.9% with diabetic and 17.5% with CHD RE complications). Among patients with 0,1,2,3 and 4 diabetic complications, patients who had incident CVD events during follow-up ranged from 4.0%-15.7%. Among patients with 0,1,2,3 and 4 CHD RE complications, the number of patients with incident CVD events increased from 2.4% to 44.8% (Figure). Similar results were found among patients aged ≥40 years. After adjusting for age, gender, region, payer type and history of CVE, risk (hazard ratio) of incident CVD events increased as the number of diabetic or CHD RE complications increased compared to those without any complications. Conclusions: T2DM patients with diabetic or CHD RE complications, despite being on standard lipid-lowering therapy have substantial residual risk for future CVD events compared to those without complications.
MiR-139-5p is a potent tumor suppressor in adult acute myeloid leukemia
Authors: K Krowiorz, J Ruschmann, C Lai, M Ngom, T Maetzig, V Martins, A Scheffold, E Schneider, N Pochert, C Miller, L Palmqvist, A Staffas, M Mulaw, S R Bohl, C Buske, M Heuser, J Kraus, K O'Neill, C L Hansen, O I Petriv, H Kestler, H Döhner, L Bullinger, K Döhner, R K Humphries, A Rouhi, F Kuchenbauer
Journal: Blood Cancer Journal (2016)
Strategies for Graft Versus Host Disease Prophylaxis after Reduced-Intensity Conditioning Transplantation: Combination of Sirolimus Plus Tacrolimus Allows to Obtain the Best Outcome
Authors: Rocío Parody, Dolores Caballero, Martinez Carmen, Rodrigo Martino, Carlos Solano, Pere Barba, Lucía López-Corral, Oriana Lopez Godino, Lourdes Vazquez, Montserrat Rovira, Francesc Fernandez-Avilés, Albert Esquirol, Irene García Cadenas, José Luís Piñana, David Valcarcel, Francisco J. Marquez-Malaver, Jose Antonio Perez-Simón
Journal: Blood (2014)
Does mammography affect the nodal status at presentation in 40- to 49-year-old breast cancer patients?
Authors: L. Hopkins, S. H. Chang, L. J. Kirstein, T. Fulop, S. C. Malamud, M. Chadha, S. K. Boolbol
Journal: Journal of Clinical Oncology (2011)

55 Background: It has previously been demonstrated that mammographically-detected breast cancers present as earlier stage disease than those detected as a palpable finding. In addition, it is well known that the single most important prognostic indicator in breast cancer is lymph node status. The benefit of screening mammography in women age 40-49 has been questioned recently, and has led to a change in the recommendations by the United States Preventative Services Task Force (USPSTF) to begin screening mammography in the average risk woman at age 50, rather than 40. In this study, we sought to determine whether detection of breast cancer in 40-49 year old women by screening mammography is associated with negative nodal status at presentation. Methods: A prospectively collected database was reviewed to identify 460 women ages 40-49 diagnosed with invasive breast cancer from 2003-2008. The method of detection of the breast cancer was noted, and the lymph node status at presentation was identified. Results: There were 460 eligible patients with invasive breast cancer for whom information regarding nodal status was available. Of these, 205 patients were diagnosed with a mammographic finding, and 255 patients presented with a palpable abnormality. In the group whose cancers were detected on mammography, 18% presented with lymph node metastases. This is significantly lower than the 41% who presented with a palpable finding (p&lt;0.0001). For 40-49 year old women with invasive breast cancer, the likelihood of having a positive lymph node at presentation is 3.2 times higher if her cancer is detected as a palpable abnormality rather than on mammography (odds ratio) (CI: 2.1-5.0) (Table). Conclusions: Our analysis demonstrates that a patient diagnosed with invasive breast cancer in her 40s is more likely to present with lymph node metastases if her cancer is detected as a palpable mass, compared to those detected on mammography. This has certain prognostic importance, and provides an additional rationale for performing screening mammography in women of this age group. [Table: see text]
A Predictive Model Using Telomere Length to Select Optimal Donors for Hematopoietic Stem Cell Transplant (HCT) for Acute Leukemia
Authors: David Loftus, Buturovic Ljubomir, Wang Tao, Spellman Stephen, Haagenson Michael, Krstajic Damjan, Shelton Jason, Marsha Blauwkamp, Hesterberg Lyndal, Friedman Lyssa, Stephanie J. Lee
Journal: Blood (2015)
Communicating risk to patients in the emergency department
Authors: Anne M Stiggelbout, J Wouter Jukema, Ellen E Engelhardt, Carla van den Bos, Arwen H Pieterse
Journal: BMJ (2016)

Shared decision making works well even in this highly charged setting

“Nothing about me without me”1 and “Really putting patients at the centre of healthcare”2 are just two expressions of the call for patient involvement and shared decision making. For many, shared decision making is becoming the norm, at least in preference sensitive decisions, but for others it is seen as just a fashionable phrase, to be followed by business as usual. Indeed, sharing decisions seems to occur to a fairly limited extent in daily practice.3 In a linked report of a noteworthy study involving patients at all stages from study design to publication, Hess and colleagues took up the challenge of supporting patient decision making in the emergency department (doi:10.1136/bmj.i6165).4 They show that even in this setting patients can be involved. With the implementation of a “quantitative pretest probability webtool” built into a decision aid for the clinical encounter, the authors more than doubled patient …
Outcomes of patients with clinical lymphadenopathy treated with radical prostatectomy.
Authors: T. T. Higuchi, R. H. Breau, E. C. Umbreit, E. J. Bergstralh, L. J. Rangel, R. Carlson, R. J. Karnes
Journal: Journal of Clinical Oncology (2011)

106 Background: Some patients with lymph node metastases experience prolonged survival following radical prostatectomy. The purpose of this study was to determine the outcome of patients with clinically suspicious lymph nodes on preoperative imaging who underwent radical prostatectomy and lymphadenectomy. Methods: Patients with lymph node metastases diagnosed during radical prostatectomy from 1988-2003 were reviewed. Patients with preoperative CT or MRI images were included in the study. Radiology reports were reviewed to determine if patients had clinically suspicious lymphadenopathy (cN+). For all analyses, patients with cN+ were compared to those with clinically negative nodes (cN−). Results: Preoperative imaging was available in 202 men with lymph node metastasis at the time of prostatectomy. Of these 17% (34/202) were cN+. None had pre-operative lymph node biopsy and none had abandoned prostatectomy. At a median follow-up of 11.1 years, PSA recurrence occurred in 50% (17/34) and 49% (82/186), local recurrence in 18% (6/34) and 13% (22/186) and systemic progression in 32% (11/34) and 24% (40/186) of patients with cN+ and cN-, respectively. On multivariate analysis, cN+ was not associated with increased risk of death (HR 1.66, p=0.1). Conclusions: cN+ patients undergoing surgical therapy for prostate cancer may experience similar outcomes to cN− patients. The presence of clinically suspicious lymph nodes on preoperative imaging should not be an absolute contraindication for surgical therapy. No significant financial relationships to disclose.
The Transcriptional Profile of PV Displays Limited Similarity to EPO Stimulated Progenitor Cells: Evidence That JAK2 V617F Confers a Novel Program to Malignant Hematopoietic Stem Cells.
Authors: Windy Berkofsky-Fessler, Melanie J. McConnell, Kai Huang, Monica L. Bailey, Dwayne L. Barber, Ross L. Levine, Donna S. Neuberg, D. Gary Gilliland, Jonathan D. Licht
Journal: Blood (2005)
Efficacy and Safety of Bosutinib (SKI-606) among Patients with Chronic Phase Ph+ Chronic Myelogenous Leukemia (CML).
Authors: J. Cortes, T. Bruemmendorf, H. Kantarjian, J. Khoury, G. Rosti, T. Fischer, L. Tornaghi, B. Hewes, E.C. Martin, C. Gambacorti-Passerini
Journal: Blood (2007)